Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
17 June 2015Next earnings report:
14 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Mon, 20 May 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
Included in screeners
ALPN Latest News
Smart investors are keeping an eye on certain biotech stocks this month, as they have seen a significant increase of over 160%. With potential for even more growth in the future, adding these stocks to a portfolio could result in substantial capital gains.
Vera Therapeutics is working on a dual-action antibody for kidney disorders, and has seen positive results in the initial stage of a key study. Vertex Pharmaceuticals recently purchased Alpine Immune Sciences, a company also developing an antibody targeting the same receptors as Vera Therapeutics' candidate.
Vertex (VRTX) plans to purchase Alpine Immune Sciences (ALPN) for $65 per share in cash, with the deal expected to be finalized by the second quarter of 2024.
The Nasdaq is showing strong performance today, with the biotech ETF SPDR S&P Biotech ETF (XBI) increasing by more than 2% on the day.
Alpine Immune Sciences received a $4.9 billion acquisition offer from Vertex Pharmaceuticals following positive news about their new autoimmune drug, Povetacicept. The drug successfully passed Phase 2 review by the FDA for treating a rare kidney disease and is now set to enter Phase 3 trials.
Alpine Immune Sciences Inc (NASDAQ: ALPN) surged 35% on Thursday following an announcement by Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) that it plans to purchase the biotech firm for $65 per share. Is Alpine Immune's stock accurately priced at $65?
Analysts stated on Thursday that Vertex Pharmaceuticals Inc.'s purchase of Alpine Immune Sciences Inc. is a strategic move that will strengthen the company's rare-disease portfolio.
Shares of Alpine Immune Sciences Inc rose even further in pre-market trading, following a significant increase on Wednesday due to the announcement of a US$4.9 billion acquisition by Vertex Pharmaceuticals Incorporated. Before the market opened, shares increased by 36.3% to US$64.10, building on the 20.8% gain from the previous day.
Vertex Pharmaceuticals announced on Wednesday that they will be purchasing Alpine Immune Sciences in a deal worth approximately $4.9 billion.
Boston biotech company Vertex Pharmaceuticals has agreed to purchase Seattle-based Alpine Immune Sciences for $65 per share, resulting in a total of approximately $4 billion.
- 1(current)
- 2
What type of business is Alpine Immune Sciences?
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
What sector is Alpine Immune Sciences in?
Alpine Immune Sciences is in the Healthcare sector
What industry is Alpine Immune Sciences in?
Alpine Immune Sciences is in the Biotechnology industry
What country is Alpine Immune Sciences from?
Alpine Immune Sciences is headquartered in United States
When did Alpine Immune Sciences go public?
Alpine Immune Sciences initial public offering (IPO) was on 17 June 2015
What is Alpine Immune Sciences website?
https://www.alpineimmunesciences.com
Is Alpine Immune Sciences in the S&P 500?
No, Alpine Immune Sciences is not included in the S&P 500 index
Is Alpine Immune Sciences in the NASDAQ 100?
No, Alpine Immune Sciences is not included in the NASDAQ 100 index
Is Alpine Immune Sciences in the Dow Jones?
No, Alpine Immune Sciences is not included in the Dow Jones index
When does Alpine Immune Sciences report earnings?
The next expected earnings date for Alpine Immune Sciences is 14 August 2024